This schematic diagram demonstrates the relationships between asparaginase (ASP) and dexamethasone (DEX) pharmacokinetics and risk of relapse as described by Kawedia et al.1 Clinical allergy and silent hypersensitivity are known to result in formation of anti-asparaginase antibodies (Abs). The authors also identify older age and several drugs that are associated with increased clearance of dexamethasone. The purple box details clinical strategies that may compensate for the altered pharmacokinetics (PK) and thus avoid the deleterious effects in terms of treatment outcome. Professional illustration by Debra T. Dartez.

This schematic diagram demonstrates the relationships between asparaginase (ASP) and dexamethasone (DEX) pharmacokinetics and risk of relapse as described by Kawedia et al. Clinical allergy and silent hypersensitivity are known to result in formation of anti-asparaginase antibodies (Abs). The authors also identify older age and several drugs that are associated with increased clearance of dexamethasone. The purple box details clinical strategies that may compensate for the altered pharmacokinetics (PK) and thus avoid the deleterious effects in terms of treatment outcome. Professional illustration by Debra T. Dartez.

Close Modal

or Create an Account

Close Modal
Close Modal